Share Together, the companies aim to advance next-generation nanofabrication processes that improve qubit performance, reliability, and scalability, paving the way for practical quantum systems that bridge scientific research and real-world application. This partnership also strengthens U.S. leadership in semiconductor research and nanofabrication while fostering local innovation and job creation across California's technology corridor. "Our collaboration represents a critical step in translating quantum co ...

Core Insights - TransCode Therapeutics, Inc. has announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate its lead therapeutic candidate TTX-MC138 in the PRE-I-SPY clinical trial platform [1][2] Group 1: Clinical Trial Details - The PRE-I-SPY program will include TTX-MC138 in a Phase 2a dose-expansion clinical trial, enrolling up to 45 patients with colorectal cancer who are ctDNA positive after standard therapy [2][3] - The Phase 2a trial is set to begin in the first half of 2026 and will be led by Dr. Paula Pohlmann from MD Anderson Cancer Center [2] Group 2: Therapeutic Potential - The trial aims to assess the biological and clinical activity of TTX-MC138 in the Minimal Residual Disease (MRD) setting, targeting patients with a high risk of recurrence [3][4] - TTX-MC138 is designed to inhibit microRNA-10b, which is believed to play a critical role in the progression of metastatic cancers [5][6] Group 3: Company Background - TransCode Therapeutics is focused on developing immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers, with TTX-MC138 being its lead candidate [6] - The company has a portfolio of first-in-class therapeutic candidates aimed at mobilizing the immune system to combat cancer cells [6] Group 4: Collaborative Efforts - Quantum Leap Healthcare Collaborative sponsors the I-SPY Trials, which aim to rapidly screen promising treatments and identify effective therapies for specific patient subgroups [7][8] - The collaboration aims to accelerate the evaluation of TTX-MC138, with the goal of advancing effective and less toxic precision therapies into later trial phases [4][8]

Core Insights - Inturai Ventures Corp. has successfully delivered quantum-safe encryption for connected devices in defense, aged care, and home security sectors, in partnership with PQStation, holding exclusive deployment rights in these areas [1][7] - The encryption technology was tested using both post-quantum cryptography (PQC) alone and in combination with traditional security, demonstrating strong performance with low delay and minimal power impact [2] - The global ESP32 module market, crucial for billions of devices, was valued at approximately $2.1 billion in 2023 and is projected to reach $4.6 billion by 2032, indicating significant growth potential for Inturai's technology [3] Industry Context - Governments in the U.S., Canada, Australia, and the EU are mandating post-quantum security upgrades to begin by 2026, with critical sectors like defense and healthcare required to be fully transitioned by 2028 [4][7] - This global momentum towards post-quantum security highlights the urgency and relevance of Inturai's early deployment advantage in securing vital systems against emerging quantum threats [4][7] - Inturai's advancements position the company at the forefront of spatial intelligence technology, enabling secure, AI-powered sensing without heavy hardware or complexity [5]

Core Viewpoint - Quantum BioPharma Ltd. has successfully closed a non-brokered private placement, issuing 30 Class A Multiple Voting Shares at a price of $25 each, resulting in gross proceeds of $750 million [1][2]. Offering Details - The securities issued are subject to a statutory hold period of four months plus a day from issuance as per Canadian securities laws [2]. - Proceeds from the offering will be utilized for general working capital purposes [2]. Related Party Transactions - Xorax Family Trust and Fortius Research and Trading Corp., both associated with company insiders, purchased all Class A Multiple Voting Shares in the offering, qualifying as a related-party transaction under MI 61-101 [3]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements as the transaction did not exceed 25% of the company's market capitalization [3]. Corporate Update - The company has terminated its at-the-market offering agreement with H.C. Wainwright & Co., effective December 6, 2025, with the termination taking effect on December 20, 2025 [16]. - No Class B Subordinate Voting Shares have been sold under the previous sales agreement, which allowed for the sale of up to $21.225 million worth of shares [17]. Debt Settlement - Quantum BioPharma has settled $260,000 owed to an arm's length creditor by issuing 17,626 Class B Subordinate Voting Shares at a deemed price of $14.75 per share [18]. Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [19]. - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until reaching $250 million, after which the royalty will drop to 3% [19].

Core Insights - Rigetti Computing (RGTI) is planning to develop a more advanced quantum chip fabrication facility to achieve >99.9% fidelity levels necessary for commercial-grade quantum systems [1][8] - The company is exploring partnerships with existing foundries, participating in U.S. government initiatives, and considering building a new 200-300mm fab to enhance process quality and qubit consistency [2][8] Company Updates - Quantum Computing Inc. (QUBT) has launched its first commercial entangled-photon source for quantum networking and secure communications [3] - QUBT is scaling production at its photonic foundry and expanding into quantum sensing and cybersecurity, indicating a shift towards commercial deployment [4] - D-Wave Quantum (QBTS) has made its Advantage2 annealing system commercially available, featuring over 4,400 qubits and enhanced performance [5][6] Market Performance - RGTI shares have increased by 84.9% year-to-date, significantly outperforming the industry growth of 9.9% [7] - The company has a price-to-book ratio of 24.69, which is above the industry average, and carries a Value Score of F [10] - The Zacks Consensus Estimate for Rigetti's 2025 earnings indicates a projected decline of 88.9% from the previous year [13]

Core Insights - Quantum Computing Inc. (QCi) is set to debut at CES 2026, showcasing its quantum photonics technology through live demonstrations that emphasize real-world applications and decision-making improvements [1][2][3] Company Overview - QCi is an innovative company specializing in integrated photonics and quantum optics technology, providing accessible quantum machines and foundry services for photonic chip production based on thin-film lithium niobate (TFLN) [5] - The company operates a unique thin film lithium niobate foundry in Tempe, Arizona, which supports photonic integrated circuit capabilities for a 150 mm wafer line [4] Product Demonstrations - At CES Foundry, QCi will conduct live demonstrations focusing on practical applications such as optimizing routes, enhancing financial outcomes, and accelerating AI training, all designed to illustrate the immediate value of quantum photonics [3][4] - The demonstrations aim to show how quantum photonics can facilitate better decision-making without requiring quantum expertise [3] Industry Context - The current landscape indicates that as AI becomes more operational, the challenge lies in making rapid, effective decisions rather than merely accessing data [2] - QCi positions quantum photonics as a viable infrastructure solution to enhance the scalability, efficiency, and trustworthiness of intelligent systems [2]

Core Viewpoint - Momentum is returning to the quantum computing sector, with IonQ, D-Wave Quantum, and Rigetti showing significant breakouts after a challenging period [1][2][14]. Group 1: Market Activity - IonQ, D-Wave Quantum, and Rigetti have all staged meaningful breakouts, indicating a potential shift in market sentiment towards the quantum computing sector [1][2]. - The stocks have formed tight bull flag patterns, suggesting that the initial breakouts are not one-off events but may lead to further upward movement [2][14]. Group 2: Stock Performance - IonQ's stock has shown constructive behavior post-breakout, trading sideways in a tight consolidation, which is characteristic of a bull flag [5][6]. - D-Wave Quantum's breakout was strong, with the stock forming a compressed bull flag and showing persistent demand during consolidation [8][9]. - Rigetti's stock has also demonstrated constructive behavior, forming a bullish wedge and finding support during small dips [11][12]. Group 3: Buy Triggers - A breakout above $55 for IonQ would confirm the continuation of its upward trend, while a close above this level with increasing volume would reinforce the bullish signal [6]. - For D-Wave Quantum, a move through $28.70 would signal the next phase of the trend, with a closing above this level increasing the odds of sustained continuation [9]. - Rigetti would signal a price advance with a push above $26.60, while a breakdown below $27.15 would invalidate the current setup [12]. Group 4: Overall Sector Outlook - The recent breakouts in IONQ, QBTS, and RGTI mark the end of a correction and the beginning of renewed momentum in the quantum computing sector, with all three stocks trading in bullish continuation patterns [14][15].

Core Viewpoint - The quantum computing sector, particularly D-Wave Quantum, is experiencing a resurgence despite previous volatility, suggesting potential growth as the technology approaches a critical inflection point [1][3][8]. Company Overview - D-Wave Quantum has seen a significant rebound, with shares increasing over 50% from their lows in November [1]. - Evercore ISI has initiated coverage on D-Wave Quantum with a target price of $44 per share, indicating confidence in the company's potential as a leading player in the quantum computing space [8][9]. Market Context - The broader market has shown skepticism towards AI and growth stocks, yet quantum stocks like D-Wave Quantum are beginning to show signs of recovery [3][4]. - The current market environment may present an opportunity for investors to consider quantum stocks, especially as they have lost about half their value in recent months [7]. Investment Considerations - The transition from pre-revenue to commercialization for quantum computing companies is critical, and if growth accelerates, share prices could rise significantly [2][6]. - D-Wave Quantum is described as well-funded, which is essential for capitalizing on upcoming opportunities in the quantum computing market [9].

Core Insights - Quantum Secure Encryption Corp (QSE) has launched qREK, a Software Development Kit (SDK) aimed at integrating post-quantum-resilient encryption into applications and systems [1][3][10] - qREK allows organizations to locally generate encryption keys using secure quantum-grade entropy, enhancing security by eliminating risks associated with cloud or remote key generation [2][7] - The launch of qREK represents a significant step in QSE's mission to modernize security measures in anticipation of vulnerabilities posed by quantum computing [3][5] Product Features - qREK enables local key generation on the client's machine, ensuring that cryptographic keys are never transmitted or exposed [7][9] - The SDK is compatible with existing cryptographic systems, including AES, RSA, and NIST-recommended post-quantum cryptography algorithms like Kyber and Dilithium [7][9] - qREK operates on a zero-trust architecture, allowing organizations to maintain control over their cryptographic lifecycle while utilizing next-generation quantum entropy [2][9] Market Positioning - QSE positions qREK as a transformative tool for developers and security teams, facilitating the integration of quantum-resilient encryption without disrupting existing workflows [6][8] - The company emphasizes the importance of qREK in preparing organizations for the post-quantum era, addressing the inadequacies of legacy key generation methods [5][6] - QSE's offerings, including qREK, aim to empower organizations to secure their data against current and future threats, thereby advancing global data security standards [10]

Core Viewpoint - Stock Trend Capital Inc. is focused on building long-term shareholder value through strategic investments in high-growth industries, with a commitment to returning 50% of net profits to shareholders as dividends [1][2]. Investment Portfolio Overview - As of October 31, 2025, Stock Trend's portfolio includes a mix of publicly traded securities and strategic investments in private companies, providing diversified exposure to key growth sectors [4]. - The company plans to deploy $1 million into new investment opportunities in 2026, aligning with its strategy to expand exposure to high-growth sectors [3]. Major Investments - The two largest investments are in Younet and eGOD Digital Labs, both of which are expected to go public in 2026, with eGOD aiming for a Nasdaq listing [2]. - Stock Trend holds significant positions in various companies, including: - Matador Technologies (30,000 shares valued at $10,200) focused on the Bitcoin ecosystem [5]. - Syntheia Corp. (600,000 shares valued at $60,000) specializing in conversational AI [5]. - AISIX (715,000 shares valued at $14,300) focusing on climate-risk analytics [5]. - Younet (26,666,667 shares valued at $1,333,333) developing personalized AI models [5]. Strategic Financing - Stock Trend entered a strategic hybrid financing initiative with eGOD Digital Labs, involving a CAD 1 million loan with a 10% annual interest rate and a maturity date of June 30, 2026 [8][9]. - The financing structure includes a revenue-based royalty of 7% until a cumulative total of CAD 500,000 is received, and the right to convert the loan and royalties into equity [9]. Company Focus - Stock Trend Capital Inc. primarily targets investments in AI, crypto, mining, quantum technology, and the Canadian cannabis industries, seeking entities with strong intellectual property and high growth potential [10].